Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.56 |
| ▸ | CA12 | O43570 | 15/20 | 0.56 |
| ▸ | CA9 | Q16790 | 15/20 | 0.56 |
| ▸ | CA1 | P00915 | 14/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL7210107 | 0.85 | CA2 (0.52) | CA2CA12CA9CA1SCN2A | |
| SCHEMBL8811870 | 0.78 | CA2 (0.59) | CA2CA12CA9CA1CA4 | |
| SCHEMBL5487533 | 0.77 | CHRNA7 (0.49) | CA2CA12CA9CA1SCN2A | |
| SCHEMBL10059528 | 0.76 | CA12 (0.54) | CA2CA12CA9CA1SCN2A | |
| SCHEMBL202948 | 0.75 | CA2 (0.81) | CA2CA12CA9CA1CA4 | |
| SCHEMBL3422896 | 0.75 | CA2 (0.54) | CA2CA12CA9CA1CA4 | |
| SCHEMBL4408673 | 0.75 | CHRNA7 (0.76) | CA2CA12CA9CA1MEN1 | |
| SCHEMBL16719356 | 0.74 | PKM (0.57) | CA2CA12CA9CA1CA4 | |
| SCHEMBL16719730 | 0.74 | KDM4E (0.52) | PKMALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL1548435 | 0.72 | CA2 (1.00) | CA2CA12CA9CA1SCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340550-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2025-08-12 | — | — | US | disclosed |
| EP-4288542-A1 | MULTI-VALENT OLIGONUCLEOTIDE AGENT AND METHODS OF USE THEREOF | Ractigen Therapeutics (CN) | 2023-12-13 | — | — | EP | disclosed |
| US-20230312566-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11773183-B2 | MUC16 monoclonal antibody and uses thereof | QUEST PHARMATECH INC. (CA) | 2023-10-03 | — | — | US | disclosed |
| CN-111454268-B | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116589465-A | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230183236-A1 | CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| CN-113710671-B | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20230070306-A1 | MONOCLONAL ANTIBODIES AGAINST HER2/NEU AND USES THEREOF | CANARIABIO INC. (KR) | 2023-03-09 | — | — | US | disclosed |
| EP-2205075-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | Tragara Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2205076-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL INHIBITORS OF EGFR ÝERBB1¨AND HER-2 ÝERBB2¨ | Tragara Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2170062-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | Tragara Pharmaceuticals, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009070547-A1 | CANCER TREATMENT USING COX-2 INHIBITOR AND ANTIMETABOLITE COMBINATIONS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070546-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009042612-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009042613-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL INHIBITORS OF EGFR [ERBB1] AND HER-2 [ERBB2] | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009009778-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105961-A1 | Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia | TOP2A, TOP2B, TOP1 | CA2 133/4885CA12 875/4885CA9 542/4885 |
| US-20250340550-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | BCL2, BAD, BAX | CA2 623/4885CA12 2668/4885CA9 3409/4885 |
| US-20230312566-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | BCL2, BAD, BAX | CA2 623/4885CA12 2668/4885CA9 3409/4885 |
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | ABL1, BTK, LYN | CA2 1141/4885CA12 3923/4885CA9 2033/4885 |
| US-20230183236-A1 | CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | BAD, BCL2, BAX | CA2 1875/4885CA12 2887/4885CA9 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.